🧬 ICD-10 CM H02.883 — Meibomian Gland Dysfunction Of Right Eye, Unspecified Eyelid
Billable Code Confirmed
ICD-10 CM H02.883 is a full 6-character, billable ICD-10-CM code⁸. The structure breaks down as H02 (other disorders of eyelid) → .88 (meibomian gland dysfunction subcategory) → 3 (right eye, eyelid unspecified as to upper or lower), giving full specificity for laterality while leaving eyelid location unspecified, which is acceptable when the provider’s documentation doesn’t distinguish upper from lower lid involvement.
Non-Billable Parent Codes
H02.88 (Meibomian gland dysfunction of eyelid) is non-billable — it lacks laterality and eyelid-location detail and requires a 6th character to be reportable⁹. H02.8 (Other specified disorders of eyelid) is non-billable — it is a broad subcategory grouping multiple unrelated eyelid conditions and cannot stand alone on a claim. H02 (Other disorders of eyelid) is non-billable — it is the category-level parent for the entire block of eyelid disorders and requires full subcategory and character specificity before use.
Clinical Context
The clinical distinction driving code selection here is laterality (right vs. left vs. unspecified eye) combined with whether the provider specified upper lid, lower lid, both lids, or left the eyelid unspecified — H02.883 applies specifically when the right eye is documented but the slit-lamp exam or note doesn’t differentiate which eyelid margin is affected.
Code Classification
This is a diagnosis code (ICD-10-CM), not a procedure code — it reports the clinical condition of meibomian gland dysfunction and carries no inherent procedural or reimbursement-driving weight on its own; any associated treatment (thermal pulsation, gland expression, probing) requires separate CPT/HCPCS reporting.
🔍 Code Description
Meibomian gland dysfunction (MGD) is a chronic, diffuse abnormality of the meibomian glands — the sebaceous glands lining the tarsal plates of the eyelids — most commonly characterized by terminal duct obstruction and/or qualitative or quantitative changes in glandular secretion¹⁰. This dysfunction disrupts the lipid layer of the tear film, leading to increased tear evaporation, ocular surface irritation, and in chronic cases, secondary changes to the H02.883 and conjunctiva. MGD is widely recognized as the leading cause of evaporative dry eye disease and frequently coexists with posterior blepharitis, for which it is often used as a near-synonymous clinical descriptor. In the inpatient and profee ophthalmology setting, MGD is rarely the primary reason for admission but is frequently documented as a comorbid or incidental finding during broader ocular surface or perioperative evaluations, particularly in patients being worked up for cataract or corneal procedures where an unstable tear film could affect surgical planning.
ICD-10 CM H02.883 specifically captures right-eye involvement where the documentation does not specify upper lid, lower lid, or both — this contrasts with the more granular sibling codes H02.881 and H02.882, which specify upper and lower right lid respectively, and H02.88A, which captures simultaneous right upper and lower lid involvement. Selecting the correct level of specificity depends entirely on what the ophthalmologist documents on slit-lamp exam; coders should never default to the unspecified-eyelid code when the note clearly states “upper lid” or “lower lid” findings, since doing so under-codes the specificity available in the record and can trigger CDI queries or payer scrutiny on audit.
🌳 Code Tree / Hierarchy
H02.88 Meibomian gland dysfunction of eyelid ❌ Non-billable
│
├── H02.881 Meibomian gland dysfunction right upper eyelid ✅ Billable
├── H02.882 Meibomian gland dysfunction right lower eyelid ✅ Billable
│
├── H02.883 Meibomian gland dysfunction of right eye, unspecified eyelid ◀ THIS CODE ✅ Billable
│
├── H02.884 Meibomian gland dysfunction left upper eyelid ✅ Billable
├── H02.885 Meibomian gland dysfunction left lower eyelid ✅ Billable
├── H02.886 Meibomian gland dysfunction of left eye, unspecified eyelid ✅ Billable
├── H02.889 Meibomian gland dysfunction of unspecified eye, unspecified eyelid ✅ Billable
├── H02.88A Meibomian gland dysfunction right eye, upper and lower eyelids ✅ Billable
└── H02.88B Meibomian gland dysfunction left eye, upper and lower eyelids ✅ Billable
Specificity Drives DRG and Documentation Integrity
Using H02.883 when the chart actually documents “upper lid meibomian gland dysfunction, right eye” under-codes to the unspecified-eyelid variant instead of the fully specific H02.881 — this doesn’t change MS-DRG weight since all sibling codes group identically, but it does create a documentation-integrity gap that can surface on internal audit or CDI review.
Tip
Always cross-check the slit-lamp exam note against the final assessment before finalizing to H02.883 — many ophthalmology notes document lid-specific findings in the exam section even when the assessment line reads generically as “MGD, right eye,” and the more specific sibling code should be used when that detail exists in the record.
✅ Includes
- Meibomitis, right eye — the term used interchangeably with MGD in many clinical notes and payer policy documents.
- Posterior blepharitis, right eye, eyelid not otherwise specified — reflects the overlapping clinical terminology between MGD and posterior lid margin disease.
- Obstructive meibomian gland disease, right eye — describes the most common MGD subtype involving terminal duct obstruction.
❌ Excludes
Excludes 1
- Q10.0-Q10.3 — Congenital malformations of eyelid: this Excludes1 note is inherited from parent category H02 and applies because congenital eyelid malformations represent structural developmental anomalies present at birth, which are fundamentally distinct from the acquired glandular dysfunction captured by H02.883 — the two conditions cannot coexist under the same coding logic since one is a birth defect and the other is an acquired secretory disorder.
Danger
The most common Excludes1 error with this code family is inadvertently reporting a congenital eyelid coloboma or similar structural anomaly alongside H02.883 when the documentation actually describes a developmental defect rather than acquired gland dysfunction — always confirm whether the provider is describing a structural versus functional eyelid abnormality before finalizing code selection.
Excludes 2
No official Excludes2 annotations exist at the H02.88 subcategory or H02.883 code level per the current ICD-10-CM tabular list¹¹. Conditions such as chalazion (H00.1) and hordeolum (H00.0) are clinically related to MGD and may coexist in the same patient, but since no formal Excludes2 note governs the relationship, coders should rely on documentation to determine whether both codes are separately supported rather than assuming an automatic combinability rule.
📋 Clinical Overview
MGD vs. Chalazion vs. Blepharitis
These three conditions are frequently confused in both clinical documentation and coding because they share overlapping anatomy and can coexist in the same patient, but they represent distinct pathological processes that require separate ICD-10-CM codes when documented. MGD reflects generalized glandular dysfunction across the tarsal plate, while chalazion represents a focal, localized granulomatous cyst from a single obstructed gland, and blepharitis (when coded separately as anterior blepharitis) involves inflammation of the lid margin and lash follicles rather than the meibomian glands themselves. Distinguishing between them matters for coding accuracy and for downstream CDI queries, since providers sometimes use these terms loosely or interchangeably in dictated notes.
| Feature | H02.883 | H00.1- (Chalazion) | Blepharitis (unspecified) |
|---|---|---|---|
| Pathology | Diffuse glandular dysfunction across the tarsal plate affecting meibum quality/flow. | Focal granulomatous cyst from a single obstructed meibomian or Zeis gland. | Inflammation of the lid margin and lash follicles, not gland-specific. |
| Chronicity | Chronic, often lifelong with symptom flares tied to environmental and hormonal factors. | Can be acute or subacute; often resolves with warm compresses or requires I&D if persistent. | Can be acute (staphylococcal) or chronic (seborrheic), varies by etiology. |
| Typical documentation cue | ”Meibomian gland dysfunction,” “posterior blepharitis,” “MGD” on slit-lamp exam. | ”Chalazion,” “lid nodule,” “granuloma” with a discrete palpable lesion. | ”Lid margin erythema,” “crusting,” “blepharitis” without a discrete mass. |
Important
Manifestations & Symptom Burden
- Ocular burning, grittiness, and foreign-body sensation, typically worse in the morning due to overnight meibum stagnation.
- Fluctuating or blurred vision related to tear film instability rather than a true refractive change.
- Eyelid margin telangiectasia, thickening, or capping of gland orifices visible on slit-lamp exam.
- Recurrent styes or chalazia as a downstream complication of chronic gland obstruction.
- Contact lens intolerance, often the presenting complaint that leads to the MGD diagnosis.
Tip
Symptom documentation alone (burning, dryness) is not sufficient to support H02.883 — the code requires an actual clinical finding of meibomian gland dysfunction on exam, typically via slit-lamp evaluation of gland expressibility and secretion quality, so coders should confirm the assessment/plan reflects an examined diagnosis rather than a symptom complaint alone.
💰 HCC Risk Adjustment
ICD-10 CM H02.883 is not mapped to any CMS-HCC or HHS-HCC category and carries no RAF weight under current risk adjustment models¹². Because MGD is classified as a low-severity, non-predictive chronic condition from a cost-utilization standpoint, its presence or absence on a claim has zero impact on capitated payment calculations, regardless of how frequently it’s documented annually. Coders should still capture it for clinical completeness and problem-list accuracy, but it should never be prioritized in HCC-capture workflows or annual wellness visit coding sweeps the way conditions like diabetic retinopathy (which does map to HCC categories) would be.
🏥 MS-DRG Assignment
| DRG | Title | Tier |
|---|---|---|
| 124 | Other Disorders of the Eye | With MCC |
| 125 | Other Disorders of the Eye | Without MCC |
ICD-10 CM H02.883 groups to MDC 02 under this two-tier DRG pairing rather than the standard three-tier CC/MCC structure¹³. As a secondary diagnosis, its presence does not itself drive DRG assignment since MGD alone does not qualify as either a CC or MCC — DRG movement to 124 requires a separately documented and coded MCC elsewhere in the record (e.g., a severe corneal complication). Sequencing as principal diagnosis is uncommon and clinically atypical for MGD, since it rarely justifies inpatient-level care on its own; when it does appear as principal diagnosis, coders should verify medical necessity documentation carefully, as payers may scrutinize an inpatient stay driven by what is typically an outpatient-managed condition.
🔗 Related ICD-10-CM Codes
Meibomian Gland Dysfunction Family: H02.881, H02.882, H02.884, H02.885, H02.886, H02.889, H02.88A, H02.88B
Related Eyelid/Ocular Surface Conditions: H00.11 (Chalazion right upper eyelid), H00.12 (Chalazion right lower eyelid), H10.813 (Conjunctivitis right eye), H16.223 (Keratoconjunctivitis sicca right eye, not specified as Sjögren’s)
🛠️ Commonly Associated CPT Codes
- 92014 — Ophthalmological services, established patient, comprehensive exam: the standard billing code for the slit-lamp visit at which MGD is diagnosed and graded via meibomian gland expression testing.
- 92012 — Ophthalmological services, established patient, intermediate exam: used for focused follow-up visits monitoring MGD severity and treatment response rather than a full comprehensive workup.
- 92002/92004 — New patient ophthalmological exam (intermediate/comprehensive): used when MGD is diagnosed at an initial consult rather than an established-patient visit.
- 67999 — Unlisted procedure, eyelid: the code most commonly used for in-office MGD treatments such as intraductal meibomian gland probing or thermal pulsation therapy, since no dedicated CPT code exists for these procedures¹⁴.
NCCI Bundling Considerations
The E/M exam codes (92012/92014) are generally not separately billable on the same date as a planned MGD procedural intervention if the exam is solely to prepare for or perform that procedure, since the exam is considered bundled into the procedural service under standard NCCI logic. A significant, separately identifiable E/M service performed the same day as a procedure may support modifier -25 if clearly documented as addressing a distinct problem beyond the procedure itself.
🔬 ICD-10-PCS Crosswalk
ICD-10-PCS does not have a direct procedural crosswalk for H02.883, since MGD is a medical diagnosis managed primarily through office-based procedures (thermal pulsation, gland expression, probing) that fall outside the inpatient operating-room procedural scope PCS was designed to capture. If an inpatient procedure were performed for a severe MGD-related complication (e.g., eyelid abscess drainage), the relevant PCS root operation would be drawn from the Drainage (0-9-9) or Extirpation tables under the Eye body system, coded independently of H02.883 itself.
💊 Coding Scenarios and Examples
Scenario 1: A 68-year-old established ophthalmology patient presents with chronic right-eye grittiness and morning crusting. Slit-lamp exam reveals capped meibomian gland orifices and thickened secretions on the right lid margin, documented generally as “right eye MGD” without specifying upper or lower lid.
- Correct coding: H02.883, 92014.
- Sequencing: H02.883 is reported as the primary diagnosis supporting the comprehensive exam code.
- CDI note: If the provider’s exam findings later specify “upper lid” involvement, a query should be sent to determine whether H02.881 would be more accurate.
Scenario 2: A patient undergoes in-office thermal pulsation treatment for right-eye MGD after failing warm compress therapy, with the provider documenting “right MGD, eyelid unspecified” in the assessment.
- Correct coding: H02.883, 67999.
- Sequencing: H02.883 supports medical necessity for the unlisted procedure code, with a detailed operative note required given the unlisted-procedure status.
- CDI note: Payer prior authorization is frequently required before the procedure date given the Category I “unlisted” status of 67999 for this indication.
Scenario 3: During an inpatient admission for cataract surgery workup, the ophthalmology consult note incidentally documents “right eye MGD, unspecified eyelid” as a secondary finding unrelated to the primary admitting diagnosis.
- Correct coding: H02.883 listed as a secondary diagnosis.
- Sequencing: The principal diagnosis remains the condition driving the inpatient stay; H02.883 is captured for completeness only.
- CDI note: Since H02.883 carries no CC/MCC weight, its inclusion does not affect DRG assignment but supports accurate severity-of-illness and problem-list documentation.
⚠️ Coding Pitfalls and Tips
- Do not default to H02.883 when the documentation specifies upper or lower lid involvement — use H02.881 or H02.882 instead to reflect the full specificity available in the chart.
- MGD is not an HCC-mapped condition, so it should never be prioritized in annual wellness visit or risk-adjustment capture workflows the way HCC-relevant ophthalmologic diagnoses are.
- 67999 requires a detailed operative note for MGD procedural treatment since it is an unlisted-procedure code with no fixed RVU — vague documentation risks claim denial.
- Symptom-only documentation (dryness, burning) without an actual exam finding of gland dysfunction does not support H02.883 — confirm an examined diagnosis exists before assigning the code.
- Watch for provider use of “meibomitis” or “posterior blepharitis” as synonyms for MGD — both map to the same H02.88x family and should not be coded as separate, additional diagnoses unless the note clearly distinguishes two distinct conditions.